Propanc Biopharma Raises $100M Crypto Fund to Advance Cancer Treatment
Australian biotech firm Propanc Biopharma has secured up to $100 million in funding from Hexstone Capital to establish a cryptocurrency-backed fund dedicated to advancing enzyme-based cancer therapies. The deal marks a rare fusion of blockchain finance and medical innovation.
A Hybrid Between Biotech and Crypto Investment
The private placement is structured as a series of convertible preferred shares, providing an initial $1 million investment and an option for up to $99 million over the next 12 months. Hexstone Capital, a family office known for investing in crypto-backed ventures, will use part of its digital asset reserves to support Propanc’s research and clinical development roadmap.Propanc CEO James Nathanielsz described the partnership as “transformational,” emphasizing that it will enhance the company’s balance sheet while fueling breakthroughs in oncology: “This collaboration positions us at the intersection of biotech and digital finance, opening new pathways for sustainable funding and innovation in cancer therapeutics.”
Funding Cancer Therapy Through Blockchain Capital
Propanc’s primary research focuses on a novel platform of proenzyme-based anti-cancer drugs designed to suppress tumor growth and prevent metastasis. The new crypto fund aims to accelerate both clinical testing and regulatory progress for these treatments. By leveraging decentralized financing, the company can maintain liquidity and investor transparency while reducing reliance on traditional capital markets.Hexstone Capital stated that its strategy is to support long-term, mission-driven projects. “The integration of blockchain liquidity with high-impact biotech R&D aligns with our philosophy of investing in innovation that benefits humanity,” said a Hexstone spokesperson.
A New Funding Model for Biotech
The Propanc–Hexstone partnership reflects a growing trend of crossover between cryptocurrency markets and life sciences. As global biotech firms struggle with rising research costs, crypto-backed capital pools could become a sustainable alternative for early-stage innovation.For Propanc, this initiative not only secures fresh funding but also symbolizes a broader movement toward financial decentralization in scientific research — where blockchain transparency meets medical progress.
Editorial Team — CoinBotLab